Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Title
Intervention Indication Therapeutic Area Year Actions
Canakinumab (ILARIS) for Cardiovascular risk reduction – Add on therapy Canakinumab (Ilaris; ACZ885) Cardiovascular disease (CVD) Cardiovascular System 2017 View  |  Download
Canakinumab adjuvant therapy for treating completely
resected non-small-cell lung cancer
Canakinumab (Ilaris; ACZ885) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Canakinumab for Schnitzler syndrome Canakinumab (Ilaris; ACZ885) Schnitzler syndrome Immunology 2021 View  |  Download
Canakinumab in addition to pembrolizumab and platinum-based chemotherapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC) Canakinumab (Ilaris; ACZ885) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications